Connection

Raymond Anton to Alcohol Drinking

Back to Details
This is a "connection" page, showing publications Raymond Anton has written about Alcohol Drinking.
Raymond Anton
Connection Strength
8.212
Alcohol Drinking
  1. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction. 2020 09; 115(9):1668-1680.
    View in: PubMed
    Score: 0.441
  2. Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2019 05; 43(5):979-987.
    View in: PubMed
    Score: 0.413
  3. Brain Glutamate, GABA, and Glutamine Levels and Associations with Recent Drinking in Treatment-Na?ve Individuals with Alcohol Use Disorder Versus Light Drinkers. Alcohol Clin Exp Res. 2019 02; 43(2):221-226.
    View in: PubMed
    Score: 0.406
  4. Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control. Alcohol Clin Exp Res. 2017 Jul; 41(7):1370-1380.
    View in: PubMed
    Score: 0.364
  5. Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study. Alcohol Clin Exp Res. 2017 May; 41(5):1054-1062.
    View in: PubMed
    Score: 0.360
  6. Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcohol Clin Exp Res. 2017 01; 41(1):179-186.
    View in: PubMed
    Score: 0.353
  7. Associations Between Recent Heavy Drinking and Dorsal Anterior Cingulate N-Acetylaspartate and Glutamate Concentrations in Non-Treatment-Seeking Individuals with Alcohol Dependence. Alcohol Clin Exp Res. 2016 Mar; 40(3):491-6.
    View in: PubMed
    Score: 0.332
  8. Commentary on Subbaraman et al. (2013) [corrected]: cravings as a mediator and moderator of drinking outcomes in the COMBINE Study. Addiction. 2013 Oct; 108(10):1745-6.
    View in: PubMed
    Score: 0.282
  9. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012 Nov; 36(11):2000-7.
    View in: PubMed
    Score: 0.256
  10. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol. 2010 Aug; 30(4):365-72.
    View in: PubMed
    Score: 0.227
  11. Editorial commentary: alcohol biomarker papers. Alcohol Clin Exp Res. 2010 Jun; 34(6):939-40.
    View in: PubMed
    Score: 0.222
  12. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcohol Clin Exp Res. 2008 Nov; 32(11):1954-61.
    View in: PubMed
    Score: 0.199
  13. Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. Alcohol Alcohol. 2008 Mar-Apr; 43(2):192-7.
    View in: PubMed
    Score: 0.188
  14. Following alcohol consumption, nontreatment-seeking alcoholics report greater stimulation but similar sedation compared with social drinkers. J Stud Alcohol. 2004 May; 65(3):330-5.
    View in: PubMed
    Score: 0.147
  15. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl). 2004 Apr; 173(1-2):32-40.
    View in: PubMed
    Score: 0.144
  16. Biomarkers as aids to identification of relapse in alcoholic patients. Recent Dev Alcohol. 2003; 16:25-38.
    View in: PubMed
    Score: 0.134
  17. The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup. J Addict Med. 2022 Jul-Aug 01; 16(4):425-432.
    View in: PubMed
    Score: 0.124
  18. Adolescent Obsessive-Compulsive Drinking Scale: an assessment tool for problem drinking. J Natl Med Assoc. 2001 Mar; 93(3):92-103.
    View in: PubMed
    Score: 0.118
  19. The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013. Am J Psychiatry. 2021 06; 178(6):548-559.
    View in: PubMed
    Score: 0.117
  20. Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. J Gen Intern Med. 2021 02; 36(2):404-412.
    View in: PubMed
    Score: 0.116
  21. Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease. Alcohol Clin Exp Res. 2020 08; 44(8):1625-1635.
    View in: PubMed
    Score: 0.113
  22. Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol. 2000 Mar; 61(2):220-4.
    View in: PubMed
    Score: 0.110
  23. Response to Dr. Mark Litt's Commentary. Alcohol Clin Exp Res. 2019 10; 43(10):2255-2256.
    View in: PubMed
    Score: 0.106
  24. Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 08 01; 201:16-22.
    View in: PubMed
    Score: 0.104
  25. Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 04 01; 197:228-235.
    View in: PubMed
    Score: 0.102
  26. Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcohol Clin Exp Res. 2018 12; 42(12):2453-2465.
    View in: PubMed
    Score: 0.100
  27. Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population. Alcohol Clin Exp Res. 2018 11; 42(11):2256-2265.
    View in: PubMed
    Score: 0.100
  28. The effect of drinking intensity and frequency on serum carbohydrate-deficient transferrin and gamma-glutamyl transferase levels in outpatient alcoholics. Alcohol Clin Exp Res. 1998 Oct; 22(7):1456-62.
    View in: PubMed
    Score: 0.100
  29. Female alcoholic outpatients and female college students: a correlational study of self-reported alcohol consumption and carbohydrate-deficient transferrin levels. J Stud Alcohol. 1998 Sep; 59(5):555-9.
    View in: PubMed
    Score: 0.099
  30. Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcohol Clin Exp Res. 2018 Apr; 42(4):751-760.
    View in: PubMed
    Score: 0.095
  31. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. Neuropsychopharmacology. 2018 05; 43(6):1247-1256.
    View in: PubMed
    Score: 0.094
  32. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry. 2017 06; 4(6):469-476.
    View in: PubMed
    Score: 0.090
  33. Reprint of Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT). Clin Chim Acta. 2017 Apr; 467:15-20.
    View in: PubMed
    Score: 0.090
  34. IFCC approved HPLC reference measurement procedure for the alcohol consumption biomarker carbohydrate-deficient transferrin (CDT): Its validation and use. Clin Chim Acta. 2017 Feb; 465:91-100.
    View in: PubMed
    Score: 0.088
  35. The use of carbohydrate deficient transferrin as an indicator of alcohol consumption during treatment and follow-up. Alcohol Clin Exp Res. 1996 Nov; 20(8 Suppl):54A-56A.
    View in: PubMed
    Score: 0.087
  36. Alcohol-Induced Stimulation Mediates the Effect of a GABRA2 SNP on Alcohol Self-Administrated among Alcohol-Dependent Individuals. Alcohol Alcohol. 2016 Sep; 51(5):549-54.
    View in: PubMed
    Score: 0.084
  37. Association between a brief alcohol craving measure and drinking in the following week. Addiction. 2016 06; 111(6):1004-10.
    View in: PubMed
    Score: 0.084
  38. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996 Mar; 53(3):225-31.
    View in: PubMed
    Score: 0.083
  39. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb; 19(1):92-9.
    View in: PubMed
    Score: 0.077
  40. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. J Consult Clin Psychol. 1994 Dec; 62(6):1116-26.
    View in: PubMed
    Score: 0.076
  41. Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014 Nov; 38(11):2826-34.
    View in: PubMed
    Score: 0.076
  42. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014 Jun; 38(6):1706-11.
    View in: PubMed
    Score: 0.074
  43. Harmonization of measurement results of the alcohol biomarker carbohydrate-deficient transferrin by use of the toolbox of technical procedures of the International Consortium for Harmonization of Clinical Laboratory Results. Clin Chem. 2014 Jul; 60(7):945-53.
    View in: PubMed
    Score: 0.073
  44. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl). 2014 Sep; 231(18):3799-807.
    View in: PubMed
    Score: 0.073
  45. Risks of alcohol use disorders related to drinking patterns in the U.S. general population. J Stud Alcohol Drugs. 2014 Mar; 75(2):319-27.
    View in: PubMed
    Score: 0.073
  46. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. J Stud Alcohol Drugs. 2014 Mar; 75(2):335-46.
    View in: PubMed
    Score: 0.073
  47. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):244-50.
    View in: PubMed
    Score: 0.068
  48. Advanced gestational age increases serum carbohydrate-deficient transferrin levels in abstinent pregnant women. Alcohol Alcohol. 2012 Nov-Dec; 47(6):683-7.
    View in: PubMed
    Score: 0.065
  49. A CRHR1 haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women. Am J Med Genet B Neuropsychiatr Genet. 2011 Dec; 156B(8):960-8.
    View in: PubMed
    Score: 0.062
  50. Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence. Alcohol Clin Exp Res. 2011 Nov; 35(11):2030-8.
    View in: PubMed
    Score: 0.060
  51. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul; 168(7):709-17.
    View in: PubMed
    Score: 0.059
  52. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009 Aug; 29(4):334-42.
    View in: PubMed
    Score: 0.053
  53. Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction. 2008 Oct; 103(10):1622-8.
    View in: PubMed
    Score: 0.050
  54. Pre-pregnancy alcohol experience attenuates typical decrease in gestational alcohol consumption in mice. Alcohol. 1986 Jan-Feb; 3(1):19-22.
    View in: PubMed
    Score: 0.041
  55. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004 Sep; 28(9):1362-70.
    View in: PubMed
    Score: 0.038
  56. Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology. 2004 Feb; 29(2):393-402.
    View in: PubMed
    Score: 0.036
  57. Inhibition of prostaglandin synthesis by indomethacin does not affect alcohol consumption in inbred mice. Alcohol Clin Exp Res. 1983; 7(4):386-8.
    View in: PubMed
    Score: 0.033
  58. Effect of prenatal alcohol exposure on consumption of alcohol and alcohol-induced sleep time in mice. Pharmacol Biochem Behav. 1983; 18 Suppl 1:325-9.
    View in: PubMed
    Score: 0.033
  59. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003 Apr; 28(4):755-64.
    View in: PubMed
    Score: 0.033
  60. Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease. Alcohol Clin Exp Res. 2001 Dec; 25(12):1729-33.
    View in: PubMed
    Score: 0.031
  61. The role of craving in alcohol use, dependence, and treatment. Alcohol Clin Exp Res. 2001 Feb; 25(2):299-308.
    View in: PubMed
    Score: 0.029
  62. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
    View in: PubMed
    Score: 0.027
  63. Recurrent detoxification may elevate alcohol craving as measured by the Obsessive Compulsive Drinking scale. Alcohol. 2000 Feb; 20(2):181-5.
    View in: PubMed
    Score: 0.027
  64. Talk is cheap: measuring drinking outcomes in clinical trials. J Stud Alcohol. 2000 Jan; 61(1):55-63.
    View in: PubMed
    Score: 0.027
  65. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999 Nov; 156(11):1758-64.
    View in: PubMed
    Score: 0.027
  66. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Psychiatry. 2019 04 01; 76(4):374-381.
    View in: PubMed
    Score: 0.026
  67. Carbohydrate-deficient transferrin levels in a female population. Alcohol Clin Exp Res. 1995 Feb; 19(1):100-3.
    View in: PubMed
    Score: 0.019
  68. Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Clin Neurosci. 1995; 3(3):145-54.
    View in: PubMed
    Score: 0.019
  69. Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl). 2013 Jun; 227(4):627-37.
    View in: PubMed
    Score: 0.017
  70. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013 Feb; 38(3):414-22.
    View in: PubMed
    Score: 0.016
  71. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009 Sep; 33(9):1582-8.
    View in: PubMed
    Score: 0.013
  72. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs. 2009 Mar; 70(2):186-96.
    View in: PubMed
    Score: 0.013
  73. Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol-specific cues. Arch Gen Psychiatry. 2001 Apr; 58(4):345-52.
    View in: PubMed
    Score: 0.007
  74. A correlational study of carbohydrate-deficient transferrin values and alcohol consumption among Hispanic college students. Alcohol Clin Exp Res. 1994 Jun; 18(3):653-6.
    View in: PubMed
    Score: 0.005
  75. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992 Dec; 16(6):1007-13.
    View in: PubMed
    Score: 0.004
  76. Sensitivity to ethanol in female mice: effects of ovariectomy and strain. Life Sci. 1985 Oct 07; 37(14):1293-300.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.